Nasal in situ gel delivery system, preparation and applications thereof
A technology of in-situ gel and drug delivery system, which was applied in the field of application in 2004, can solve the problems that there are no research reports on NGF in-situ gel preparations, and achieve quality control, good biocompatibility, and stable performance. Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0028] Example 1 Prescription Optimization of Nasal In Situ Gel Delivery System
[0029] The present invention selects 31°C, which is lower than the physiological temperature of the nasal cavity and higher than the indoor temperature, as the in-situ gel screening index to optimize the preparation process and prescription of the nasal in-situ gel preparation.
[0030] In the experiment, it was found that when poloxamer P407 was used alone, its phase transition temperature (Tsol-gel) from solution to gel increased with the decrease of P407 concentration ( figure 1 shown), and the concentration had a significant effect on Tsol-gel. For example, if the concentration of P407 solution is reduced from 16% to 15%, Tsol-gel will increase from 29.2°C to 36.9°C, and a 1% difference in P407 concentration will bring about a phase change temperature difference of nearly 8°C for Tsol-gel. Moreover, after it forms a gel, its strength is low and it is easily deformed. This characteristic of ...
Embodiment 2
[0037] The preparation process and prescription of embodiment 2NGF nasal in situ gel preparation
[0038] The process for preparing the NGF nasal in situ gel preparation is a two-bottle method. One of the bottles is the nasal in situ gel solution described in Example 1, and the other bottle is the NGF freeze-dried powder preparation. Add the gel solution to the NGF freeze-dried powder before use, and mix well. NGF lyophilized powder contains NGF drug, mannitol and albumin. The dosage of NGF is 0.05%-0.1%, the dosage of albumin is 0.1%-0.2%, and the dosage of mannitol is 5%.
Embodiment 3
[0039] Example 3 Quality Evaluation of Nasal In Situ Gel Spray
[0040] According to the spray quality evaluation method described in the 2010 edition of the Chinese Pharmacopoeia, the spray volume of the nasal in situ gel drug delivery system in Example 1 was investigated. The investigation temperatures were 5°C, 20°C, 25°C, 30°C and 35°C, respectively. The research results showed that the amount per spray of the in-situ gel preparation tended to decrease with the increase of the use temperature, but the relative deviation between the amount per spray and the marked amount did not exceed 20%, which met the quality requirements of the Pharmacopoeia for sprays. Even if the storage temperature reaches 35°C, which is already higher than the gelation temperature of the preparation, the preparation exists in a gel state in the spray bottle, but the gel can be sprayed out due to the high shear stress generated during the pressing process, and every time The spray volume also meets ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com